Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
F. Sanz, J. Blanquer, E. Fernández, A. Cervera, C. Aguar, E. Chiner, R. Blanquer (Valencia, Spain). Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP). Eur Respir J 2008; 32: Suppl. 52, 1858

Member's Comments

No comment yet.

Related content which might interest you: Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2003; 22: Suppl. 45, 2s Year: 2003 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Differences between local and systemic inflammatory response in patients with community acquired pneumonia (CAP) Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia Year: 2011 An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Community-aquired pneumonia: systemic and local inflammatory response in treatment failure Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Clinical pulmonary infection score (CPIS) and inflammatory response in patients with new pulmonary infiltrates and suspected ventilator acquired pneumonia (VAP) Source: Annual Congress 2005 - Diagnosis and prognosis of ventilator associated pneumonia: the clinical track Year: 2005 Evaluation of severity, inflammatory response and adherence to treatment guidelines impact on community-acquired pneumonia outcomes Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 The impact of time on the systemic inflammatory response in pneumococcal pneumonia Source: Eur Respir J 2010; 35: 614-618 Year: 2010 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Systemic cytokine levels in community-acquired pneumonia and their association with disease severity Source: Eur Respir J 2002; 20: 990-995 Year: 2002 Systemic cytokine response in patients with community-acquired pneumonia Source: Eur Respir J 2011; 37: 1431-1438 Year: 2011 Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)? Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Respiratory pathogens, immunodeficiency or systemic response – What comes first in the etiology of severe community-acquired pneumonia (sCAP) Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009